journal
https://read.qxmd.com/read/38590149/amiodarone-induced-psoriasiform-dermatitis
#1
LETTER
Myriam Agrebi, Dhouha Sahnoun, Najet Ghariani, Mohamed Denguezli, Chaker Ben Salem
No abstract text is available yet for this article.
April 8, 2024: Annals of Pharmacotherapy
https://read.qxmd.com/read/38571388/clinical-outcomes-associated-with-diltiazem-use-in-heart-failure-with-reduced-ejection-fraction-after-implementation-of-a-clinical-support-system
#2
JOURNAL ARTICLE
Elizabeth M Foster, James C Coons, Elena A Puccio, Danine Sullinger, Rachel Ibrahim, Joseph Ibrahim, Gavin W Hickey, Edward Horn, Vincent Mosesso, Ryan M Rivosecchi
BACKGROUND: Despite atrial fibrillation guideline recommendations, many patients with heart failure with reduced ejection fraction (EF) continue to receive IV diltiazem for acute rate control. OBJECTIVE: Our institution recently implemented a clinical decision support system (CDSS)-based tool that recommends against the use of diltiazem in patients with an EF ≤ 40%. The objective of this study was to evaluate outcomes of adherence to the aforementioned CDSS-based tool...
April 3, 2024: Annals of Pharmacotherapy
https://read.qxmd.com/read/38566315/capivasertib-a-novel-akt-inhibitor-approved-for-hormone-receptor-positive-her-2-negative-metastatic-breast-cancer
#3
REVIEW
Alexa J Luboff, David L DeRemer
OBJECTIVE: To review the pharmacology, efficacy, and safety of capivasertib for the treatment of adults with hormone receptor-positive, HER2-negative (HR+/HER2-) locally advanced or metastatic breast cancer with 1 or more PIK3CA/AKT1/PTEN alterations. DATA SOURCES: A literature search was conducted using PubMed and MEDLINE databases, published abstracts, and studies from ClinicalTrials.gov between 2003 and February 2024. Keywords included capivasertib, AZD5363, PI3K/AKT/mTOR pathway, and breast cancer...
April 2, 2024: Annals of Pharmacotherapy
https://read.qxmd.com/read/38563565/role-of-a-pharmacist-in-postdischarge-care-for-patients-with-kidney-disease-a-scoping-review
#4
REVIEW
Melanie M Manis, Jessica W Skelley, J Braden Read, Rebecca Maxson, Emma O'Hagan, Jessica L Wallace, Edward D Siew, Erin F Barreto, Samuel A Silver, Sandra L Kane-Gill, Javier A Neyra
OBJECTIVE: The objective was to explore and describe the role of pharmacists in providing postdischarge care to patients with kidney disease. DATA SOURCES: PubMed, Embase (Elsevier), CINAHL (Ebscohost), Web of Science Core Collection, and Scopus were searched on January 30, 2023. Publication date limits were not included. Search terms were identified based on 3 concepts: kidney disease, pharmacy services, and patient discharge. Experimental, quasi-experimental, observational, and qualitative studies, or study protocols, describing the pharmacist's role in providing postdischarge care for patients with kidney disease, excluding kidney transplant recipients, were eligible...
April 2, 2024: Annals of Pharmacotherapy
https://read.qxmd.com/read/38563554/vaccines-for-respiratory-syncytial-virus-prevention-in-older-adults
#5
REVIEW
Daniel Wroblewski, Lindsay A Brust-Sisti, Matthew Bridgeman, Mary Barna Bridgeman
OBJECTIVE: This review evaluates the efficacy and safety of novel respiratory syncytial virus (RSV) vaccines approved for adults aged 60 years and older. DATA SOURCES: A literature search through February 27, 2024 was conducted using search terms, such as RSV, viral respiratory illness, vaccine, RSVpreF, RSVpreF3, Prefusion F, Abrysvo, and Arexvy. STUDY SELECTION AND DATA EXTRACTION: Data from primary literature and vaccine prescribing information were reviewed, encompassing evaluations of clinical pharmacology, efficacy, safety, adverse events, warnings, and precautions...
April 2, 2024: Annals of Pharmacotherapy
https://read.qxmd.com/read/38546138/live-biotherapeutic-products-for-the-prevention-of-recurrent-clostridioides-difficile-infection
#6
REVIEW
Natasha N Pettit, Kristy M Shaeer, Elias B Chahine
OBJECTIVE: To review the efficacy, safety, and role of live biotherapeutic products (LBPs) in the prevention of recurrent Clostridioides difficile infection (rCDI). DATA SOURCES: A literature search was performed using PubMed and Google Scholar (through February 2024) with search terms RBX2660, SER-109, and fecal microbiota. Other resources included abstracts presented at recent conferences, national clinical practice guidelines, and manufacturers' websites. STUDY SELECTION AND DATA EXTRACTION: All relevant studies, trial updates, conference abstracts, and guidelines in the English language were included...
March 28, 2024: Annals of Pharmacotherapy
https://read.qxmd.com/read/38533739/rozanolixizumab-a-new-therapy-in-the-treatment-of-myasthenia-gravis
#7
REVIEW
Emily M Hitt
OBJECTIVE: The aims of this article are to review the clinical aspects of rozanolixizumab, to describe clinical trial results that led to the drug's approval, and to examine the impact on patient care to aid clinical decision making. DATA SOURCES: A PubMed search was conducted using the terms Rystiggo ™, rozanolixizumab , rozanolixizumab therapy , and myasthenia gravis . The most recent prescribing information was also used for information relating to the drug and for identification of pertinent studies...
March 27, 2024: Annals of Pharmacotherapy
https://read.qxmd.com/read/38533735/increased-theophylline-plasma-concentrations-in-a-patient-with-covid-19
#8
LETTER
Miriam Rodríguez Fernández, Ana Concepción Sánchez Cerviño, Ana Codonal Demetrio, Nagore Lois Martínez, Benito García Díaz
No abstract text is available yet for this article.
March 27, 2024: Annals of Pharmacotherapy
https://read.qxmd.com/read/38506414/low-intensity-statin-plus-ezetimibe-versus-moderate-intensity-statin-for-primary-prevention-a-population-based-retrospective-cohort-study-in-asian-population
#9
JOURNAL ARTICLE
Minji Jung, Beom-Jin Lee, Sukhyang Lee, Jaekyu Shin
BACKGROUND: While moderate-intensity statin therapy is recommended for primary prevention, statins may not be utilized at a recommended intensity due to dose-dependent adverse events, especially in an Asian population. However, evidence supporting the use of low-intensity statins in primary prevention is limited. OBJECTIVE: We sought to compare clinical outcomes between a low-intensity statin plus ezetimibe and a moderate-intensity statin for primary prevention...
March 20, 2024: Annals of Pharmacotherapy
https://read.qxmd.com/read/38501850/cytomegalovirus-treatment-in-solid-organ-transplantation-an-update-on-current-approaches
#10
REVIEW
Karen L Hardinger, Daniel C Brennan
OBJECTIVE: The article reviews the safety and efficacy of treatments for cytomegalovirus (CMV) in solid organ transplantation. DATA SOURCES: A literature review was conducted in PubMed, MEDLINE, and Clinicaltrials.gov from database inception through January 2024, using terms CMV, therapy, and solid organ transplantation. STUDY SELECTION AND DATA EXTRACTION: Clinical trials, meta-analyses, cohort studies, case reports, and guidelines were included...
March 19, 2024: Annals of Pharmacotherapy
https://read.qxmd.com/read/38501811/evaluation-of-clinical-outcomes-associated-with-phenobarbital-with-taper-compared-to-no-taper-for-the-management-of-alcohol-withdrawal-syndrome
#11
JOURNAL ARTICLE
Matthew Thaller, Adrian Wong, Tuyen Yankama, Ifeoma Mary Eche, Pansy Elsamadisi
BACKGROUND: Phenobarbital (PHB) has been shown to be an effective treatment of alcohol withdrawal syndrome (AWS), with multiple dosing strategies used (e.g., single-dose and symptom-triggered). Studies have often used tapered doses, typically following a front-loaded dose, despite PHB's long half-life which should lead to an ability to auto-taper. OBJECTIVE: The purpose of this study was to compare clinical outcomes associated with two PHB dosing strategies (taper [T], no taper [NT]) for AWS...
March 19, 2024: Annals of Pharmacotherapy
https://read.qxmd.com/read/38486351/the-effect-of-albumin-replacement-on-vasopressor-duration-in-septic-shock-in-patients-with-hypoalbuminemia
#12
JOURNAL ARTICLE
Jacob P Counts, Joshua Arnold, Sara Atyia, Stella Ogake, Rachel M Smith, Bruce Doepker
BACKGROUND: The use of albumin resuscitation in septic shock is only recommended in patients who have received large volumes of crystalloid resuscitation regardless of serum albumin concentration. The role of albumin is still largely debated and evidence to support its use still lacking. OBJECTIVE: The objective of this study was to evaluate whether albumin replacement increases the number of vasopressor-free days in patients with septic shock and hypoalbuminemia...
March 14, 2024: Annals of Pharmacotherapy
https://read.qxmd.com/read/38407147/safety-profile-of-selective-serotonin-reuptake-inhibitors-in-real-world-settings-a-pharmacovigilance-study-based-on-fda-adverse-event-reporting-system
#13
JOURNAL ARTICLE
Yi Zhao, Yuzhou Zhang, Lin Yang, Kanghuai Zhang, Sha Li
BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) are the most frequently prescribed agents to treat depression. Considering the growth in antidepressant prescription rates, SSRI-induced adverse events (AEs) need to be comprehensively clarified. OBJECTIVE: This study was to investigate safety profiles and potential AEs associated with SSRIs using the Food and Drug Administration Adverse Event Reporting System (FAERS). METHODS: A retrospective pharmacovigilance analysis was conducted using the FAERS database, with Open Vigil 2...
February 26, 2024: Annals of Pharmacotherapy
https://read.qxmd.com/read/38407124/incidence-of-hypertriglyceridemia-in-patients-on-propofol-clevidipine-or-both
#14
JOURNAL ARTICLE
Christopher B Johns, Travis W Fleming, Skyler R Brown, Rebekah B Black, A Shaun Rowe
BACKGROUND: Propofol and clevidipine (PC) are commonly used in the treatment of critically ill patients. While both medications are lipid emulsions, there is limited evidence concerning the incidence of hypertriglyceridemia (HTG) when these agents are used individually or concurrently. OBJECTIVE: The objective of this study is to determine the effects of propofol, clevidipine, or concurrent PC on triglycerides (TGs) and related outcomes in critically ill adults...
February 26, 2024: Annals of Pharmacotherapy
https://read.qxmd.com/read/38389166/sugammadex-use-outside-of-the-postoperative-setting
#15
JOURNAL ARTICLE
Hayley T Gartner, Megan A Rech
BACKGROUND: Sugammadex rapidly reverses the nondepolarizing neuromuscular blocking agents (NMBAs) rocuronium and vecuronium. The role of sugammadex is not well-defined outside of the postoperative setting. OBJECTIVE: This study aims to describe sugammadex use outside the postoperative setting for the reversal of nondepolarizing NMBAs. METHODS: This was a single-center, retrospective cohort study conducted in patients who received sugammadex outside of the postoperative setting at an academic medical center between June 2016 and November 2022...
February 22, 2024: Annals of Pharmacotherapy
https://read.qxmd.com/read/38380630/eye-drop-quality-issues-can-the-fda-see-this-one-through
#16
EDITORIAL
Lyla R White, C Michael White
The Food and Drug Administration (FDA) has long suffered from a lack of resources limiting their inspection capacity. They have fallen behind on proactive surveillance inspections of foreign manufacturing sites, relying instead on for-cause inspections after a problem has been discovered. Over-the-counter (OTC) products are especially vulnerable because the FDA considers them lower priority. This issue recently made big news after improperly manufactured OTC eye drops harmed users across the country, in some cases causing blindness...
February 21, 2024: Annals of Pharmacotherapy
https://read.qxmd.com/read/38361242/preoperative-amiodarone-and-primary-graft-dysfunction-in-heart-transplantation
#17
JOURNAL ARTICLE
Abigail Servais, Scott Lundgren, Stephanie Bowman, Douglas Stoller, Adam Burdorf, Marshall Hyden, Brian Lowes, Ronald Zolty, Don Klepser, Heidi Brink
BACKGROUND: Preoperative amiodarone effects on postorthotopic heart transplant (OHT) outcomes remain controversial. OBJECTIVE: The purpose of this study was to determine the effect of cumulative pre-OHT amiodarone exposure on severe primary graft dysfunction (PGD). METHODS: We retrospectively reviewed adult OHT recipients between August 2012 and June 2018. Primary outcome was severe PGD in patients receiving amiodarone at 3, 6, and 12 months prior to OHT compared with those not receiving amiodarone...
February 15, 2024: Annals of Pharmacotherapy
https://read.qxmd.com/read/38347713/exploring-safety-in-gender-affirming-hormonal-treatments-an-observational-study-on-adverse-drug-events-using-the-food-and-drug-administration-adverse-event-reporting-system-database
#18
JOURNAL ARTICLE
Ainhoa Gomez-Lumbreras, Lorenzo Villa-Zapata
BACKGROUND: People with gender dysphoria are treated with hormone therapy for gender reassignment. The indication of this therapy was initially for the opposite sex, and information on potential adverse drug reaction (ADR) is lacking. OBJECTIVE: To describe ADR associated with gender transition medication in transgender individuals reported to the US Food and Drug Administration Adverse Event Reporting System (FAERS) database. METHODS: Data from the FAERS database up to June 2023 were examined, focusing on reports of gender transition medication use in the context of gender dysphoria...
February 12, 2024: Annals of Pharmacotherapy
https://read.qxmd.com/read/38347703/evaluation-of-short-versus-long-courses-of-antibiotics-in-critically-ill-patients-with-gram-negative-bloodstream-infections
#19
JOURNAL ARTICLE
Daniel T Anderson, Divisha Sharma, Aaron M Chase, Zoheb Irshad Sulaiman, August H Anderson, Ashley L Huggett, Joshua Eudy
BACKGROUND: Short courses of antibiotics (7-10 days) are effective for uncomplicated gram-negative bloodstream infections (GN-BSI). However, prior studies have been limited to small cohorts of critically ill patients. OBJECTIVE: The objective of this study was to evaluate the safety and efficacy of short courses of therapy compared with longer courses in patients admitted to the intensive care unit (ICU) with GN-BSI. METHODS: Propensity-matched, retrospective cohort study of critically ill patients with GN-BSI...
February 12, 2024: Annals of Pharmacotherapy
https://read.qxmd.com/read/38344998/mirikizumab-a-new-therapeutic-option-for-the-treatment-of-ulcerative-colitis
#20
REVIEW
David Choi, Hilary Sheridan, Shubha Bhat
OBJECTIVE: To review the pharmacologic and clinical profile of mirikizumab in the treatment of moderate to severe ulcerative colitis (UC). DATA SOURCES: A PubMed search was performed from inception to December 2023 using keywords mirikizumab, interleukin-23 inhibitor , and UC . Information was also obtained from package inserts as well as published abstracts. STUDY SELECTION AND DATA EXTRACTION: Phase 3 studies plus relevant literature on mirikizumab pharmacologic and clinical profile were reviewed...
February 12, 2024: Annals of Pharmacotherapy
journal
journal
20312
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.